X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs ALEMBIC PHARMA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA ALEMBIC PHARMA FULFORD INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 398.8 29.0 1,374.9% View Chart
P/BV x 6.2 6.6 93.9% View Chart
Dividend Yield % 0.1 0.7 11.9%  

Financials

 FULFORD INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
ALEMBIC PHARMA
Mar-16
FULFORD INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs942792 119.0%   
Low Rs450443 101.6%   
Sales per share (Unadj.) Rs691.4167.0 413.9%  
Earnings per share (Unadj.) Rs11.538.2 30.0%  
Cash flow per share (Unadj.) Rs15.442.0 36.6%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.30.6 44.3%  
Book value per share (Unadj.) Rs380.084.9 447.6%  
Shares outstanding (eoy) m3.90188.52 2.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.03.7 27.2%   
Avg P/E ratio x60.716.2 375.4%  
P/CF ratio (eoy) x45.314.7 308.2%  
Price / Book Value ratio x1.87.3 25.2%  
Dividend payout %17.410.5 166.5%   
Avg Mkt Cap Rs m2,714116,383 2.3%   
No. of employees `0000.4NA-   
Total wages/salary Rs m5054,214 12.0%   
Avg. sales/employee Rs Th6,073.0NM-  
Avg. wages/employee Rs Th1,137.4NM-  
Avg. net profit/employee Rs Th100.7NM-  
INCOME DATA
Net Sales Rs m2,69631,487 8.6%  
Other income Rs m12555 227.6%   
Total revenues Rs m2,82231,542 8.9%   
Gross profit Rs m-4610,060 -0.5%  
Depreciation Rs m15722 2.1%   
Interest Rs m1037 25.8%   
Profit before tax Rs m549,356 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m102,160 0.4%   
Profit after tax Rs m457,194 0.6%  
Gross profit margin %-1.731.9 -5.4%  
Effective tax rate %17.723.1 76.6%   
Net profit margin %1.722.8 7.3%  
BALANCE SHEET DATA
Current assets Rs m1,73815,066 11.5%   
Current liabilities Rs m5457,674 7.1%   
Net working cap to sales %44.323.5 188.6%  
Current ratio x3.22.0 162.6%  
Inventory Days Days4867 72.4%  
Debtors Days Days441 10.6%  
Net fixed assets Rs m128,237 0.1%   
Share capital Rs m39377 10.3%   
"Free" reserves Rs m1,44315,416 9.4%   
Net worth Rs m1,48216,005 9.3%   
Long term debt Rs m00-   
Total assets Rs m2,07724,594 8.4%  
Interest coverage x6.7255.2 2.6%   
Debt to equity ratio x00-  
Sales to assets ratio x1.31.3 101.4%   
Return on assets %2.629.4 8.9%  
Return on equity %3.044.9 6.7%  
Return on capital %4.358.7 7.3%  
Exports to sales %055.7 0.0%   
Imports to sales %24.510.4 234.5%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs m6593,283 20.1%   
Fx inflow Rs m1717,811 0.1%   
Fx outflow Rs m6735,318 12.7%   
Net fx Rs m-65612,493 -5.3%   
CASH FLOW
From Operations Rs m909,304 1.0%  
From Investments Rs m105-3,105 -3.4%  
From Financial Activity Rs m-14-1,959 0.7%  
Net Cashflow Rs m1814,240 4.3%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 2.9 131.0%  
FIIs % 0.1 9.1 1.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 13.9 152.5%  
Shareholders   4,783 49,328 9.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - J.B.CHEMICALS COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS